ARNA - Arena Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Arena Pharmaceuticals, Inc.

6154 Nancy Ridge Drive
San Diego, CA 92121
United States
858-453-7200
http://www.arenapharm.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees194

Key Executives

NameTitlePayExercisedYear Born
Mr. Amit D. MunshiPres, CEO & Director1.11MN/A1968
Mr. Kevin R. LindExec. VP & CFO648.57kN/A1976
Mr. Steven W. SpectorExec. VP, Gen. Counsel & Sec.700.15k1.02M1965
Mr. Vincent E. AurentzExec. VP & Chief Bus. Officer751.46kN/A1968
Dr. Preston S. KlassenExec. VP and Head of R&D667.37kN/A1969
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Axovant Sciences GmbH; Outpost Medicine LLC; CY Biotech Company Limited; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Corporate Governance

Arena Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 3. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.